Brief: Antengene Corp Says Selinexor Included In 2023 National Reimbursement Drug List
14/12/2023 01:25
Dec 14 (Reuters) - Antengene Corporation Ltd 6996.HK :
* SELINEXOR, ANTENGENE'S NEW DRUG, SUCCESSFULLY INCLUDED IN
2023
NATIONAL REIMBURSEMENT DRUG LIST
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106